Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Academic Article uri icon

Overview

MeSH

  • Acetylcholine
  • Adult
  • Aged
  • Drug Eruptions
  • Edema
  • Exercise Test
  • Exercise Tolerance
  • Femoral Artery
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Infusions, Intra-Arterial
  • Injections, Intramuscular
  • Leg
  • Nitroglycerin
  • Regional Blood Flow
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

MeSH Major

  • Adenoviridae
  • Endothelial Growth Factors
  • Endothelium, Vascular
  • Genetic Vectors
  • Lymphokines
  • Peripheral Vascular Diseases

abstract

  • Vascular endothelial growth factor (VEGF) currently is being evaluated in clinical angiogenesis trials involving patients with peripheral arterial disease. We hypothesized that delivery of VEGF to the skeletal muscle of the lower extremity using an adenoviral vector (Ad(GV)VEGF(121.10)) would improve peripheral endothelial function. Accordingly, we investigated lower-extremity endothelial function in patients enrolled in a Phase I adenovirus-mediated gene delivery trial of VEGF(121.10). Blood flow to the index extremity was measured by thermodilution at baseline and 30 days after administration of Ad(GV)VEGF(121.10), in response to the infusion of endothelium-dependent and -independent agonists (acetylcholine and nitroglycerin, respectively) into the ipsilateral femoral artery. There was no difference in basal flow before or after treatment with Ad(GV)VEGF(121.10). In response to acetylcholine (150 microg/min and 300 microg/min), there was a 0.9-fold (0.33+/-0.03 to 0.32+/-0.03 L/min) and 1.2-fold (0.33+/-0.03 to 0.490+/-0.02 L/min) change in flow before Ad(GV)VEGF(121.10) treatment. After Ad(GV)VEGF(121.10) treatment, flow increased 2.4-fold (0.310+/-0.04 to 0.730+/-0.10 L/min) and 2.3-fold (0.31+/-0.04 to 0.7+/-0.08 L/min), respectively (P<0.05 before Ad(GV)VEGF(121.10) treatment versus after Ad(GV)VEGF(121.10) for both doses). Infusion of nitroglycerin resulted in a 1.8-fold increase in flow before Ad(GV)VEGF(121.10) (0.33+/-0.03 to 0.58+/-0.06 L/min) compared with a 2.4-fold increase (0.31+/-0.04 to 0.73+/-0.09 L/min) after Ad(GV)VEGF(121.10) (P=NS before Ad(GV)VEGF(121.10) versus after Ad(GV)VEGF(121.10)). Lower-extremity flow reserve increased in all patients in response to at least 1 dose of acetylcholine. Peak walking times increased concomitant with improvement in endothelial function. Adenoviral gene transfer of VEGF(121.10) appears to modulate endothelial function and lower-extremity flow reserve in patients with peripheral arterial disease.

publication date

  • August 14, 2001

has subject area

  • Acetylcholine
  • Adenoviridae
  • Adult
  • Aged
  • Drug Eruptions
  • Edema
  • Endothelial Growth Factors
  • Endothelium, Vascular
  • Exercise Test
  • Exercise Tolerance
  • Femoral Artery
  • Gene Transfer Techniques
  • Genetic Therapy
  • Genetic Vectors
  • Humans
  • Infusions, Intra-Arterial
  • Injections, Intramuscular
  • Leg
  • Lymphokines
  • Nitroglycerin
  • Peripheral Vascular Diseases
  • Regional Blood Flow
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Research

keywords

  • Clinical Trial
  • Clinical Trial, Phase I
  • Journal Article

Identity

Language

  • eng

PubMed ID

  • 11502697

Additional Document Info

start page

  • 753

end page

  • 755

volume

  • 104

number

  • 7